- Home
- MHO vs VKTX Comparison
MHO vs VKTX Comparison
Compare MHO & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHO
- VKTX
- Stock Information
- Founded
- MHO 1976
- VKTX 2012
- Country
- MHO United States
- VKTX United States
- Employees
- MHO N/A
- VKTX N/A
- Industry
- MHO Homebuilding
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- MHO Consumer Discretionary
- VKTX Health Care
- Exchange
- MHO Nasdaq
- VKTX Nasdaq
- Market Cap
- MHO 3.2B
- VKTX 3.4B
- IPO Year
- MHO 1986
- VKTX 2015
- Fundamental
- Price
- MHO $116.79
- VKTX $34.07
- Analyst Decision
- MHO Buy
- VKTX Strong Buy
- Analyst Count
- MHO 3
- VKTX 14
- Target Price
- MHO $176.50
- VKTX $97.29
- AVG Volume (30 Days)
- MHO 350.9K
- VKTX 4.9M
- Earning Date
- MHO 01-29-2025
- VKTX 02-05-2025
- Dividend Yield
- MHO N/A
- VKTX N/A
- EPS Growth
- MHO 21.59
- VKTX N/A
- EPS
- MHO 19.71
- VKTX N/A
- Revenue
- MHO $4,504,670,000.00
- VKTX N/A
- Revenue This Year
- MHO $4.65
- VKTX N/A
- Revenue Next Year
- MHO $7.64
- VKTX $986.87
- P/E Ratio
- MHO $5.93
- VKTX N/A
- Revenue Growth
- MHO 11.68
- VKTX N/A
- 52 Week Low
- MHO $109.92
- VKTX $28.64
- 52 Week High
- MHO $176.18
- VKTX $99.41
- Technical
- Relative Strength Index (RSI)
- MHO 36.48
- VKTX 51.41
- Support Level
- MHO $112.83
- VKTX $28.90
- Resistance Level
- MHO $121.96
- VKTX $34.37
- Average True Range (ATR)
- MHO 3.71
- VKTX 2.37
- MACD
- MHO 0.26
- VKTX 0.66
- Stochastic Oscillator
- MHO 36.23
- VKTX 70.06
About MHO M/I Homes Inc.
M/I Homes Inc is an American construction company that focuses on residential construction. It consists of two distinct operations: homebuilding and financial services. The homebuilding operations are spread into the Midwest, Mid-Atlantic, and Southern regions, and the financial services operations support homebuilding operations by providing mortgage loans and title services to the customers of homebuilding operations. Homebuilding operations comprise a predominant portion of the revenue. The company builds homes and communities that target entry-level, move-up, and luxury homebuyers.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.